Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several ...

Three critically ill patients treated with procizumab experience a full reversal of cardiogenic shock in 48 hours.

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

Matchpoint Therapeutics partners with Novartis to develop oral covalent inhibitors for inflammatory diseases, with potential ...

Swiss pharma major Novartis (NOVN: VX) has entered into an exclusive option and license deal with Matchpoint Therapeutics to ...

Novartis and Matchpoint Therapeutics have entered into a partnership worth $1bn to develop oral inhibitors for inflammatory ...

The Revell family hoped a gene therapy could buy time for their sons, who have a rare and fatal disease. After two patients died, the drug’s manufacturer halted dosing under pressure from the FDA.

We recently published 8 Stocks That Jim Cramer Recently Talked About. Novartis AG (NYSE:NVS) is one of the stocks Jim Cramer ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Novartis AG stands third among the most undervalued ...

Avalere Health, a 2025 MM+M Agency 100 honoree, named Rhiannon Meaden, PhD, as head of medical strategy and transformation.

SWX:NOVN Earnings and Revenue History July 24th 2025 The Impact Of Unusual Items On Profit. To properly understand Novartis' profit results, we need to consider the US$2.8b expens ...